Navigation Links
Mass. Eye and Ear Researcher receives RPB Award
Date:7/20/2012

Boston (July 20, 2012) The Massachusetts Eye and Ear Infirmary and Harvard Medical school has been granted a $250,000 Research to Prevent Blindness (RPB) Career Development Award to support the work of Mass. Eye and Ear ophthalmologist Dr. Joseph Ciolino.

Dr. Ciolino obtained his medical degree from Georgetown University School of Medicine, and completed an Internal Medicine internship at Brown University and his ophthalmology residency at Albany Medical College, where he served as Chief Resident in his final year. He completed a fellowship in the Cornea, Refractive Surgery and External Disease Service at Mass. Eye and Ear, where he received the nationally recognized Claes Dohlman Fellowship Award. Following his fellowship, Dr. Ciolino joined Harvard Medical School's full time faculty at Mass. Eye and Ear. His clinical focus is in corneal transplants, keratoprosthesis and diseases of the anterior segment of the eye.

Dr. Ciolino's research interests include translational projects such as keratoprosthesis and ocular drug delivery. He has been working with collaborators at Children's Hospital Boston and MIT on developing a drug-eluting contact lens which has been covered by international news services including CNN, Reuters News Service, and Scientific American.

The RPB Career Development Award Fund was established in 1990 to attract young physicians and basic scientists to eye research. To date, the program has recruited 164 vision scientists to research positions in departments of ophthalmology at universities across the country.


'/>"/>

Contact: Vannessa Carrington
Vannessa_Carrington@meei.harvard.edu
617-573-3341
Massachusetts Eye and Ear Infirmary
Source:Eurekalert

Page: 1

Related medicine news :

1. Mass. Eye and Ear and HMS department of ophthalmology receives RPB Grant
2. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
3. UGA researchers develop rapid diagnostic test for pathogens, contaminants
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
6. Nursing researcher uses Nintendo Wii to fight cancer-related fatigue
7. Researchers to use novel metabolomics technology for COPD
8. Researchers hit back at early bodycheck theory
9. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
10. Researchers developing new multiple sclerosis drug that can be taken orally
11. Ordinary chickens may be extraordinary in fighting cancer, says Texas A&M researcher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: